11 June 2026
: Case report
[In Press] Single-Site ALK-Positive Histiocytosis With TFG-ALK Fusion: Expanding the Clinical Spectrum of This Rare Entity
Rare disease
Mona Dasgupta1BCDEF, David Horvath2BCDE, Benjamin Bevill1A, Ashley Scheiderer2BCDE, Sean Jordan3AEFDOI: 10.12659/AJCR.952807
Am J Case Rep In Press; DOI: 10.12659/AJCR.952807
Available online: 2026-06-11, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Anaplastic lymphoma kinase (ALK)-positive histiocytosis is a rare and recently described histiocytic neoplasm characterized by ALK gene rearrangements. Several ALK fusion partners have been reported, particularly in patients with multisystem disease. We report the first case of single-site ALK-positive histiocytosis involving a TFG-ALK fusion, a rearrangement previously linked to disseminated disease.
CASE REPORT
A man in his 50s with obesity, obstructive sleep apnea, diabetes mellitus, hypertension, coronary artery disease, and a 40-pack-year smoking history underwent computed tomography for lung cancer screening; the results showed a solitary 1.6-cm left lower lobe pulmonary nodule. Positron emission tomography demonstrated hypermetabolic activity confined to the lesion. He subsequently underwent video-assisted thoracoscopic wedge resection with mediastinal lymphadenectomy. Histopathologic evaluation revealed a well-circumscribed spindle cell neoplasm expressing histiocytic markers CD4, CD68, and CD163, with cytoplasmic ALK positivity. A TFG-ALK gene fusion was detected using Archer FusionPlex Pan Solid Tumor panel testing with anchored multiplex polymerase chain reaction via Illumina NextSeq 500. Immunohistochemical and flow cytometric studies excluded alternative ALK-rearranged neoplasms, including inflammatory myofibroblastic tumor, anaplastic large cell lymphoma, and ALK-positive diffuse large B-cell lymphoma. The patient received no systemic therapy and remains disease-free on radiographic surveillance.
CONCLUSIONS
To our knowledge, this case represents the first reported instance of single-site ALK-positive histiocytosis with a TFG-ALK fusion. It expands the molecular and clinical spectrum of this rare entity, suggesting that certain ALK fusion partners are associated with localized disease and an indolent clinical course. Recognition of such presentations is essential to avoid unnecessary systemic therapy.
Keywords: Anaplastic Lymphoma Kinase; Gene Fusion; Histiocytosis; Immunohistochemistry; Thoracic Surgery
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






